A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects

Summary

TQF3250 capsule is a biased GLP-1 (glucagon-like peptide-1) receptor agonist developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. By binding to the GLP-1 receptor, it can selectively activate certain signaling pathways of the GLP-1 receptor and reduce activation of other pathways, thereby bringing higher efficacy and lower side effects.

Timeline

Start

2025-12-18

Primary completion

2026-12

Completion

2026-12

Drugs

Indications